Form 4: Vaxart CFO Jeroen Grasman Receives Stock Options and Restricted Stock Units

Jeroen Nicolaas Grasman, CFO of Vaxart, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• Jeroen Nicolaas Grasman, the Chief Financial Officer of Vaxart, Inc., filed a Form 4 on May 20, 2025.
• The filing reports transactions made on May 19, 2025.
• Grasman acquired 350,000 shares of common stock upon the vesting of restricted stock units.
• He also acquired options to purchase 1,000,000 shares of common stock at an exercise price of $0.4998.
• The restricted stock units vest 25% annually starting May 19, 2025, becoming fully vested on May 19, 2029.
• The stock options vest as to 25% of the shares on May 19, 2026, and then in 36 equal monthly installments, becoming fully vested on May 19, 2029.
• Following these transactions, Grasman directly owns 350,000 shares and options for 1,000,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and restricted stock units is a standard practice and suggests confidence in the company's future performance. It aligns the CFO's interests with those of the shareholders.

Positives

• The vesting of restricted stock units and grant of stock options to the CFO could be seen as an incentive to align his interests with those of the shareholders.
• The vesting schedule of both the restricted stock units and stock options is spread out over several years, which may encourage long-term commitment from the CFO.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice in the biotech industry.
• Companies like Moderna, BioNTech, and Novavax also utilize similar compensation strategies to incentivize their executives.
• The vesting schedules and exercise prices are generally benchmarked against industry peers to ensure competitiveness and alignment with company performance.

Stakeholder Impact

• Shareholders may view the grant of stock options and restricted stock units positively, as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Vaxart, VXRT, Jeroen Grasman, CFO, Form 4, Stock Options, Restricted Stock Units, Vesting